What is the relationship between Tepotinib and Pembrolizumab?

Tepotinib and pembrolizumab are two different drugs with different mechanisms of action and indications, and there is no direct relationship between them. If you need to use two drugs at the same time, it is recommended to consult a doctor and use them according to the doctor's advice and guidance.

Tepotinib is a tyrosinase inhibitor mainly used to treat certain special types of non-small cell lung cancer. It can inhibit the activity of tyrosinase in tumor cells, inhibit the proliferation and spread of tumor cells, and thus play an anti-tumor role. The adverse reactions of tepotinib include fatigue, nausea, vomiting, diarrhea, etc., and it needs to be used under the guidance of a doctor. Pembrolizumab is an immune checkpoint inhibitor mainly used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, etc. It can inhibit the immunosuppressive effect mediated by immunosuppressive cytokines, promote the activation and proliferation of immune cells, and thus play an anti-tumor role. Adverse reactions of pembrolizumab include immune-related adverse reactions, such as rash, pneumonia, colitis, hepatitis, etc.

The original drug Tepotinib is already on the market in China, but it is not yet eligible for medical insurance. Tepotinib Original drug currently marketed overseas is relatively expensive, and the price of each box of 225mg*30 tablets may be around RMB 80,000 (the price may fluctuate due to exchange rates). There are already generic Tepotinib drugs produced in other countries. The ingredients of these generic drugs are basically the same as those of the original drug, but the price is relatively cheap. For example, the price of 225mg*60 tablets produced by a Laos pharmaceutical factory may be more than 8,000 yuan per box (the price may fluctuate due to exchange rates).